

07 May 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly's donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 May 2023, including: strong growth in blockbuster ranks in 2022; [Eli Lilly and Company's](#) donanemab slow cognitive decline; FDA approves first RSV vaccine; [Pfizer Inc.](#) anticipates revenue bolus from vaccines; and [Astellas Pharma, Inc.](#) buys into ophthalmology.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks](#)" - Scrip, 1 May, 2023.)

(Also see "[Lilly's Donanemab Slows Cognitive Decline; FDA Filing Imminent](#)" - Scrip, 3 May, 2023.)

(Also see "[GSK's Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow](#)" - Scrip, 3 May, 2023.)

(Also see "[Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year](#)" - Scrip, 2 May, 2023.)

(Also see "[\*Astellas Paying \\$5.9bn For Iveric To Boost Ophthalmology Presence\*](#)" - Scrip, 1 May, 2023.)

[\*Click here to explore this interactive content online\*](#) ✨